Guardian Pharmacy Services (GRDN) to Release Earnings on Wednesday

Guardian Pharmacy Services (NYSE:GRDN) will likely be announcing its Q1 2026 results after the market closes on Wednesday, May 6th. Analysts expect the company to announce earnings of $0.24 per share and revenue of $329.8910 million for the quarter. Investors can check the company’s upcoming Q1 2026 earning summary page for the latest details on the call scheduled for Wednesday, May 6, 2026 at 4:30 PM ET.

Guardian Pharmacy Services (NYSE:GRDN) last announced its quarterly earnings results on Wednesday, March 11th. The company reported $0.37 earnings per share for the quarter, topping analysts’ consensus estimates of $0.27 by $0.10. The company had revenue of $397.62 million during the quarter, compared to analysts’ expectations of $390.04 million. Guardian Pharmacy Services had a return on equity of 31.64% and a net margin of 3.40%.The company’s quarterly revenue was up 17.4% compared to the same quarter last year. On average, analysts expect Guardian Pharmacy Services to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Guardian Pharmacy Services Stock Performance

Shares of NYSE:GRDN traded down $0.39 during midday trading on Monday, hitting $36.99. The company’s stock had a trading volume of 31,664 shares, compared to its average volume of 368,789. The stock’s 50 day simple moving average is $35.85 and its 200 day simple moving average is $32.03. The stock has a market capitalization of $2.34 billion, a price-to-earnings ratio of 48.03, a PEG ratio of 2.48 and a beta of 0.09. Guardian Pharmacy Services has a fifty-two week low of $19.17 and a fifty-two week high of $41.36.

Wall Street Analyst Weigh In

A number of brokerages recently commented on GRDN. Truist Financial upped their target price on Guardian Pharmacy Services from $38.00 to $43.00 and gave the company a “buy” rating in a research note on Monday, April 13th. Wall Street Zen raised shares of Guardian Pharmacy Services from a “buy” rating to a “strong-buy” rating in a report on Saturday, April 25th. Weiss Ratings restated a “hold (c+)” rating on shares of Guardian Pharmacy Services in a research note on Friday, March 27th. Raymond James Financial reiterated an “outperform” rating and set a $40.00 target price on shares of Guardian Pharmacy Services in a research report on Thursday, March 12th. Finally, Zacks Research raised shares of Guardian Pharmacy Services from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, March 18th. One analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has issued a Hold rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus price target of $40.50.

Insider Buying and Selling at Guardian Pharmacy Services

In other news, insider Fred Burke sold 671,432 shares of the firm’s stock in a transaction dated Friday, March 20th. The stock was sold at an average price of $29.68, for a total transaction of $19,928,101.76. Following the sale, the insider owned 840,413 shares of the company’s stock, valued at $24,943,457.84. This trade represents a 44.41% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, major shareholder Equity Fund L.P. Cardinal sold 275,728 shares of Guardian Pharmacy Services stock in a transaction that occurred on Friday, March 20th. The shares were sold at an average price of $29.68, for a total transaction of $8,183,607.04. Following the completion of the transaction, the insider directly owned 345,123 shares in the company, valued at approximately $10,243,250.64. The trade was a 44.41% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 9,726,405 shares of company stock valued at $288,679,700 over the last quarter. 32.96% of the stock is owned by corporate insiders.

Institutional Trading of Guardian Pharmacy Services

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Valiant Capital Management L.P. boosted its holdings in shares of Guardian Pharmacy Services by 15.8% in the 4th quarter. Valiant Capital Management L.P. now owns 1,232,463 shares of the company’s stock valued at $37,085,000 after buying an additional 167,741 shares during the last quarter. Wellington Management Group LLP grew its position in shares of Guardian Pharmacy Services by 3.3% in the 3rd quarter. Wellington Management Group LLP now owns 1,143,729 shares of the company’s stock valued at $30,000,000 after acquiring an additional 36,072 shares during the period. Franklin Resources Inc. increased its stake in shares of Guardian Pharmacy Services by 8.2% during the 3rd quarter. Franklin Resources Inc. now owns 1,056,240 shares of the company’s stock worth $27,705,000 after purchasing an additional 80,033 shares during the last quarter. Vanguard Group Inc. raised its holdings in shares of Guardian Pharmacy Services by 9.1% in the 3rd quarter. Vanguard Group Inc. now owns 1,055,102 shares of the company’s stock valued at $27,675,000 after purchasing an additional 88,296 shares during the period. Finally, Boston Partners lifted its stake in Guardian Pharmacy Services by 0.7% in the 4th quarter. Boston Partners now owns 1,054,636 shares of the company’s stock valued at $31,995,000 after purchasing an additional 7,759 shares during the last quarter.

Guardian Pharmacy Services Company Profile

Guardian Pharmacy Services, Inc, a pharmacy service company, provides a suite of technology-enabled services designed to help residents of long-term health care facilities (LTCFs) in the United States. Its individualized clinical, drug dispensing, and administration capabilities are used to serve the needs of residents in lower acuity LTCFs, such as assisted living facilities and behavioral health facilities and group homes. The company’s Guardian Compass includes dashboards created using data from its data warehouse to help its local pharmacies plan, track, and optimize their business operations; and GuardianShield Programs for LTCFs.